MAPT and Cognitive impairment: Remarkably, EGCG decreases Aβ levels and plaques in mice, reduced Aβ mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice (Lee et al. 2009; Rezai-Zadeh et al. 2005, 2008), as well as prevents Aβ-induced mitochondrial dysfunction, impairment of NMDA Ca2+ influx and ROS production (He et al. 2011).